Skip to Content

Fusilev Approval History

Fusilev (levoleucovorin calcium) is a folate analog indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, and for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

Development History and FDA Approval Process for Fusilev

May  2, 2011Approval FDA Approves Fusilev for Use in Patients with Colorectal Cancer
Mar 10, 2008Approval FDA Approves New Drug Application for Levoleucovorin, Spectrum's First Proprietary Oncology Drug
Sep 13, 2007FDA Accepts ISO-Vorin New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
Jul  2, 2007Spectrum Pharmaceuticals Completes the NDA Filing for Isovorin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.